Pyroptosis Modulates Cancer Progression and Antitumor Immunity

Stephen Wang^*
*Correspondence: Stephen Wang, Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany, Email:

Introduction

Cell death is necessary for organismal growth and development to maintain in vivo stability. Cell death can be broken down into two groups: intentional and unintentional cell death. By-accident cell death is caused by uncontrolled noxious physical, chemical, or mechanical stimuli. In contrast, PCD is a form of protective suicide that promotes morphogenesis while eliminating undesirable or abnormal cells. A pro-inflammatory PCD called pyroptosis is used to fight infection and endogenous danger signals. Cell inflammatory necrosis is another name for it. Canonical pyroptosis, which is dependent on caspase-1, and non-canonical pyroptosis, which is not, are the two types of pyroptosis. Numerous cancers, including non-small cell lung cancer, colorectal cancer, gastric cancer, and hepatocellular carcinoma, are linked to inflammation. The treatment of neurological diseases would benefit from additional pyroptosis research as well. Studies have demonstrated that pyroptosis promotes immune cell activity, which in turn promotes tumor regression. However, the connection between pyroptosis and antitumor immunity is still unknown. Cancer cell biological mutation increases inflammatory reactions in the tumor microenvironment, which successfully encourages antitumor immunity, whereas immune cell pyroptosis is responsible for the protection of a host against a pathogen infection. Tumor growth is affected by both CCP and ICP taken together. During carcinogenesis, pyroptosis is a double-edged sword that is currently up for debate. The development of novel and effective cancer treatment options will be aided by a thorough comprehension of the pyroptosis that occurs in the cells of the tumor [1].

Chromatin condensation, cell membrane rupture, endoplasmic reticulum expansion, and the production of IL-1 as an inflammatory response were all mentioned in descriptions of the phenomena known as pyroptosis. The first identification and naming of the effector of pyroptosis occurred in 2000. Before Brennan and Cookson discovered that macrophages infected with Salmonella typhimurium perished through an inflammatory death mechanism as opposed to the conventional type of apoptosis, pyroptosis was thought to be a particular type of apoptotic cell death in monocytes. Pyroptosis is characterised by its rapid onset, rapid destruction of the cell membrane's integrity, and strong inflammatory reaction. However, this important finding went unnoticed at the time, and the precise chemical mechanism of pyroptosis is still unknown [2]. An attempt was made to replace the word "caspase-activating complex," which initiates the inflammatory caspases. Pyroptosis, an inflammatory cell death, is crucial for the development of both immunity and malignancy. Pyroptosis may affect carcinogenesis differently depending on the surroundings and resulting in radically different outcomes when treating cancer. The traditional cancer treatment options include chemotherapy and radiation. However, both cancer cells and healthy cells, including immune cells, are promptly eliminated by these treatments. Immunotherapy activates the body's natural defences to destroy cancer cells. Cancer cells can use ESCRT-mediated membrane repair to avoid the immune system's "search" for them. The CHMP4B deletion improved the ability of CTLs to destroy cancer cells by inhibiting the ESCRT pathway [3].

Cell death is necessary for organismal growth and development to maintain in vivo stability. Cell death can be broken down into two groups: intentional and unintentional cell death. By-accident cell death is caused by uncontrolled noxious physical, chemical, or mechanical stimuli. In contrast, PCD is a form of protective suicide that promotes morphogenesis while eliminating undesirable or abnormal cells. A pro-inflammatory PCD called pyroptosis is used to fight infection and endogenous danger signals. Cell inflammatory necrosis is another name for it [4]. Canonical pyroptosis, which is dependent on caspase-1, and non-canonical pyroptosis, which is not, are the two types of pyroptosis. Numerous cancers, including non-small cell lung cancer, colorectal cancer, gastric cancer, and hepatocellular carcinoma, are linked to inflammation. The treatment of neurological diseases would benefit from additional pyroptosis research as well. Studies have demonstrated that pyroptosis promotes immune cell activity, which in turn promotes tumor regression. However, the connection between pyroptosis and antitumor immunity is still unknown. Cancer cell biological mutation increases inflammatory reactions in the tumor microenvironment, which successfully encourages antitumor immunity, whereas immune cell pyroptosis is responsible for the protection of a host against a pathogen infection. Tumor growth is affected by both CCP and ICP taken together. During carcinogenesis, pyroptosis is a double-edged sword that is currently up for debate. The development of novel and effective cancer treatment options will be aided by a thorough comprehension of the pyroptosis that occurs in the cells of the tumor [5].

Conclusion

Pyroptosis, in contrast to apoptosis and ferroptosis, is accompanied by a significant inflammatory response and the rupture of cells. In this section, we discussed the relationship between pyroptosis and cancer development. To begin, pyroptosis can be initiated by a variety of stimulation signals, including PAMPs, DAMPs, pharmacological stimulations, and granzymes. The majority of stimuli are communicated by activating gasdermins, which in turn activate granzymes and caspases. When gasdermin is cleaved by active caspases or granzymes, its N-terminus, which punches the cell membrane, is exposed. During pyroptosis, intracellular inflammatory mediators IL-1 and IL-18 are released to cause inflammation and cell death. Cancer and pyroptosis are increasingly linked, according to research. However, the connection between pyroptosis and cancer is currently unknown.

Pyroptosis, on the one hand, has the ability to successfully control the immunological milieu of a tumor, elicit a potent antitumor immune response mediated by T cells, halt the growth of a tumor, and increase the sensitivity of cancer cells to chemotherapeutic drugs. On the other hand, pyroptosis provides a favorable environment for the growth of tumors because it is a process of cell death that encourages inflammation. As a result, new strategies for treating cancer could be developed through research into the pyroptosis mechanism. The relationship between pyroptosis and tumor immunity also provides significant insights into cancer drugs because pyroptosis is an essential component of tumor immunity and tumor immunotherapy.

References

1. Zychlinsky, Arturo, Marie Christine Prevost and Philippe J. Sansonetti. “Shigella flexneri induces apoptosis in infected macrophages.” Nature 358 (1992): 167-169.

Google Scholar, Crossref, Indexed at

2. Martinon, Fabio, Kimberly Burns and Jürg Tschopp. “The Inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-β.” Mol Cell 10 (2002): 417-426.

Google Scholar, Crossref, Indexed at

3. Zhang, Zhibin, Ying Zhang, Shiyu Xia and Qing Kong, et al. “Gasdermin E suppresses tumour growth by activating anti-tumour immunity.” Nature 579 (2020): 415-420.

Google Scholar, Crossref, Indexed at

4. Hou, Junwei, Jung-Mao Hsu and Mien-Chie Hung. “Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity.” Mol Cell 81 (2021): 4579-4590.

Google Scholar, Crossref, Indexed at

5. Voskoboinik, Ilia, James C. Whisstock and Joseph A. Trapani. “Perforin and granzymes: Function, dysfunction and human pathology.” Nat Rev Immunol 15 (2015): 388-400.

Google Scholar, Crossref, Indexed at